Speed Post News Network
New Delhi : Union Minister for Chemicals & Fertilisers DV Sadananda Gowda informed the Lok Sabha in written replies on March 17, 2020, that fixation of prices has resulted in a total saving of Rs 12,447 crores per annum to the public after implementation of the DPCO, 2013.
National Pharmaceutical Pricing Authority (NPPA) fixes the ceiling price of scheduled formulations adopted from National List of Essential Medicines (NLEM) and new drugs as per the provisions of para 4, 5 and 6 of the Drugs (Prices Control) Order, 2013 (DPCO, 2013). Further, the prices of non-scheduled formulation are monitored so that their MRP is not increased by more than 10% of MRP during preceding twelve months. NPPA fixed the ceiling prices of 530 scheduled formulations under NLEM, 2011. The Minister elaborated steps taken by NPPA for making medicine available at affordable price, according to a PIB release.
NPPA fixed prices of 106 Anti-diabetic and Cardiovascular drugs under Para 19 of DPCO, 2013 in Public interest. It has fixed ceiling price of Cardiac Stents being scheduled formulation under DPCO, 2013 affecting price reduction for Coronary Stents worked out up to 85% for Bare Metal Stents and 74% for Drug Eluting Stents.
NPPA has fixed ceiling price of Orthopedic Knee Implants under Para 19 of DPCO, 2013 in Public interest affecting price reduction for orthopedic Knee Implants worked out up to be 69%. It capped the Trade Margin of non-scheduled formulations of 42 select Anti-cancer medicine under “Trade Margin Rationalisation” approach as a Pilot for proof of concept, wherein price of above 500 brands of medicine were reduced up to 90%.